GSK Upbeat On RSV Vaccines, Hepatitis B Therapy
Walmsley Flags Future Growth Drivers
Executive Summary
GlaxoSmithKline's executive team outlined the progress the company is making against COVID-19, lupus nephritis, ovarian cancer and multiple myeloma.
You may also be interested in...
GSK's Growth Drivers And Cost Containment Offset Pandemic Impact
GlaxoSmithKline’s third quarter results included a 9% decline in sales in its vaccine business, but this was offset by tight cost controls and restructuring benefits; the company expects to continue investing in its pipeline and new product launches.
GSK To Address Multiple Myeloma With First-In-Class Blenrep In EU
The European Commission’s approval of GlaxoSmithKline’s Blenrep is one of the first major fruits of a refocused pipeline and development strategy at the big pharma company.
EU Fast-Track Loss For GSK's Dostarlimab
GSK’s potential endometrial cancer treatment dostarlimab is one of two products to revert to standard review timelines in recent weeks.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports